Ha... I just finished putting something together!
There's been so much emotion and opinion today I thought I'd just stick with what I got from Acadia's Earnings Call. My one comment is that I'm personally not surprised by the price action today - this is how the game is played.
- There’s currently 850 patients on Daybue.
- Persistency rate at 7 months is 63%.
- Compliance rate is 75-80%.
- Current average patient weight is in the low 30kgs (v. 27kg used to estimate average pricing at time of launch).
- Current average patient age is 16 years.
- Zero drop-out rate in the patients who rolled over from the Lilac 2 trial.
- Expected Q1 2024 sales of US$76-82m, reflecting closure of most Rett clinics in January with sales pulled forward into December 23 in anticipation.
- Full FY expectation is US$370-420m, including the US$76-82m estimate for Q1.
- Management sees ample opportunity to continue to grow sales. They expect Daybue sales to increase significantly both over 2024 and in the years to come.
- Forums
- ASX - By Stock
- NEU
- Ann: DAYBUE net sales US$87.1 million in Q4 2023
Ann: DAYBUE net sales US$87.1 million in Q4 2023, page-74
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.62 |
Change
-0.240(1.15%) |
Mkt cap ! $2.635B |
Open | High | Low | Value | Volume |
$20.45 | $20.62 | $20.26 | $4.698M | 229.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 221 | $20.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.62 | 1553 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 221 | 20.600 |
1 | 10 | 20.560 |
3 | 1119 | 20.550 |
1 | 665 | 20.510 |
1 | 193 | 20.500 |
Price($) | Vol. | No. |
---|---|---|
20.620 | 1553 | 1 |
20.670 | 1121 | 1 |
20.680 | 1084 | 2 |
20.690 | 1000 | 1 |
20.700 | 483 | 1 |
Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |